ArticleMolecular medicine (Cambridge, Mass.)2026
Serum sCD163 indicates disease severity and prognosis in sudden sensorineural hearing loss.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSudden sensorineural hearing loss (SSNHL) is a rapid, unexplained decline in hearing, typically affecting one ear. Potential causes include viral infections, vascular events, and autoimmune disorders. Diagnosis is based on clinical presentation and audiometric testing, while corticosteroids remain the primary treatment to enhance recovery.
methodsThis study analyzed 257 patients with SSNHL and 100 healthy controls. Serum soluble scavenger receptor CD163 (sCD163) levels were measured using ELISA. Patients were categorized by the severity of hearing loss and audiometric curve patterns. Clinical outcomes were evaluated based on treatment response and biomarker levels.
resultsSSNHL patients exhibited significantly higher sCD163 levels than healthy controls (p < 0.001). Increased sCD163 levels were associated with greater hearing loss severity (p < 0.05). Patients who responded to treatment had lower sCD163 levels compared to those with poor treatment outcomes (p < 0.001). ROC analysis demonstrated that sCD163 had good diagnostic value in predicting treatment response (AUC = 0.79). When combined with D-dimer and fibrinogen levels, the predictive accuracy improved further (AUC = 0.89).
conclusionElevated sCD163 levels in SSNHL patients suggest its involvement in inner ear inflammation and disease severity. As a potential biomarker, sCD163 may aid in diagnosing SSNHL and predicting treatment response, underscoring its clinical utility in guiding therapeutic strategies and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.